What is Harbin Pharmaceutical Group Co., Ltd.'s (600664.SS) StockRank?

MoatMap's StockRank for Harbin Pharmaceutical Group Co., Ltd. (600664.SS) is 81/100, with a Strong Buy signal. This is a composite score combining Quality (60), Value (56), and Momentum (52) factor ranks across MoatMap's 20,000+ stock universe.

Does Harbin Pharmaceutical Group Co., Ltd. have an economic moat?

Harbin Pharmaceutical Group Co., Ltd. (600664.SS) has a Quality factor score of 60/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Harbin Pharmaceutical Group Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Harbin Pharmaceutical Group Co., Ltd. (600664.SS) is Strong Buy, based on a StockRank of 81/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Harbin Pharmaceutical Group Co., Ltd. in?

Harbin Pharmaceutical Group Co., Ltd. (600664.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

600664.SS

STRONG BUYREMOVE

Harbin Pharmaceutical Group Co., Ltd. · Healthcare · China · $1.3B · Avg Vol: $32M/d

StockRank

P/E (TTM)

26.3x

ROE

5.3%

D/E

0.2x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Harbin Pharmaceutical is a generic drug manufacturer in China. It faces intense domestic price competition and lacks the high-moat, proprietary CDMO pricing power we seek.

COMPANY DESCRIPTION

Harbin Pharmaceutical Group Co., Ltd. manufactures and distributes a wide range of pharmaceutical products, including antibiotics, over-the-counter (OTC) medicines, and nutritional supplements. The company leverages its highly recognized "Hayao" brand and a massive domestic distribution network to maintain a strong market position. It operates as a leading generic drug manufacturer with a strategic focus on expanding its consumer health and pediatric portfolios.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	2.0B	2.3B	2.4B	2.4B	5.0%
EPS	0.03	0.02	0.04	0.02	-9.7%
Shares	2.5B	2.5B	2.5B	2.5B	-0.3%
Debt	319M	276M	262M	184M	-16.8%
Equity	640M	698M	791M	841M	9.5%
Op CF	92M	140M	117M	65M	-10.9%
Inv CF	11M	-31M	-15M	-21M	—
Fin CF	26M	22M	-19M	-68M	—

PRICE (1M)-13.8%

SMA 50SMA 200

$0.46

RSI (14)

37.3

52W High

$0.72

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

9.0%70.1

ROE

5.3%57.0

GP/Assets

28.2%62.2

Op. Margin

5.3%55.1

FCF/Assets

4.4%68.5

Piotroski

—83.4

Int. Cover

14.5x69.9

D/E Ratio

0.18x54.4

Current Ratio

1.45x23.9

Value

P/E (TTM)

26.3x43.0

EV/EBITDA

9.3x44.5

P/FCF

90.8x76.0

P/B

1.4x69.9

P/S

0.5x92.8

Div Yield

—N/A

Momentum

52W High %

64%46.8

RS 6M

-24%49.7

SMA 50/200

1.00x61.3

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—82.5

Q Growth

-24%22.1

FUNDAMENTALS

Market Cap

$1.3B

P/E (Forward)

10.5x

Gross Margin

25.1%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 600664.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
600664.SS	Harbin Pharmaceutical Group Co., Ltd.(you)	$1.3B	81	STRONG BUY
603367.SS	Cisen Pharmaceutical Co., Ltd.	$934M	81	STRONG BUY
002332.SZ	Zhejiang Xianju Pharmaceutical Co.,Ltd.	$1.2B	87	STRONG BUY
002390.SZ	Guizhou Xinbang Pharmaceutical Co., Ltd.	$870M	81	STRONG BUY
002737.SZ	Sunflower Pharmaceutical Group Co.,Ltd	$1.1B	88	STRONG BUY
600993.SS	Mayinglong Pharmaceutical Group Co., Ltd.	$1.5B	88	STRONG BUY
600420.SS	Shanghai Shyndec Pharmaceutical Co., Ltd.	$1.8B	85	STRONG BUY
002349.SZ	Jinghua Pharmaceutical Group Co., Ltd.	$866M	85	STRONG BUY
002437.SZ	HARBIN GLORIA PHARMACEUTICALS Co., LTD	$975M	73	BUY
605507.SS	Guobang Pharma Ltd.	$1.8B	88	STRONG BUY

Peer medians: ROE 4.7% · P/E 27.9x · Gross margin 53.1%

Harbin Pharmaceutical Group Co., Ltd. (600664.SS) — Stock Score Summary

Harbin Pharmaceutical Group Co., Ltd. (600664.SS) has a MoatMap StockRank of 81/100 based on Quality (60/100), Value (56/100), and Momentum (52/100) factor scores. The current signal is STRONG BUY. Harbin Pharmaceutical is a generic drug manufacturer in China. It faces intense domestic price competition and lacks the high-moat, proprietary CDMO pricing power we seek.

Key Financial Metrics

Price	$0.46
Market Cap	$1.3B
P/E (TTM)	26.33
P/E (Forward)	10.53
Price/Book	1.36
Return on Equity	5.3%
Return on Invested Capital	9.0%
Debt/Equity	18.38
Gross Margin	25.1%
Operating Margin	5.3%
Revenue Growth	0.0%
Free Cash Flow	$14M

Harbin Pharmaceutical Group Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Harbin Pharmaceutical Group Co., Ltd.’s (600664.SS) StockRank?: MoatMap’s StockRank for Harbin Pharmaceutical Group Co., Ltd. (600664.SS) is 81/100, with a Strong Buy signal. It is a composite of Quality (60), Value (56), and Momentum (52) factor ranks across MoatMap’s 20,000+ stock universe.
Does Harbin Pharmaceutical Group Co., Ltd. have an economic moat?: Harbin Pharmaceutical Group Co., Ltd. (600664.SS) has a Quality factor score of 60/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Harbin Pharmaceutical Group Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Harbin Pharmaceutical Group Co., Ltd. (600664.SS) is Strong Buy, based on a StockRank of 81/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Harbin Pharmaceutical Group Co., Ltd. in?: Harbin Pharmaceutical Group Co., Ltd. (600664.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).